Use of rituximab in adults with relapsing–remitting multiple sclerosis: a systematic literature review

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Luessi F, Siffrin V, Zipp F. Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Rev Neurother. 2012;12(9):1061–1077.
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.
   PubMed Web of Science ®Google Scholar
• Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3–4):132–141.
   PubMed Web of Science ®Google Scholar
• Jongen PJ. Health-related quality of life in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs. 2017;31(7):585–602.
   PubMed Web of Science ®Google Scholar
• Krieger SC, Cook K, De Nino S, et al. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e279.
   PubMed Web of Science ®Google Scholar
• Farber RS, Sand IK. Optimizing the initial choice and timing of therapy in relapsing–remitting multiple sclerosis. Ther Adv Neurol Disord. 2015;8(5):212–232.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9:S5–S48.
   PubMed Web of Science ®Google Scholar
• Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Special Pharma. 2017;23(8):844–852.
   PubMedGoogle Scholar
• Fernandez O. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? Mult Scler Relat Disord. 2017;17:75–83.
   PubMed Web of Science ®Google Scholar
• Rituxan (rituximab) prescribing information. Revised April 2016. San Francisco (CA): Genentech; 2016.
   Google Scholar
• Rahmanzadeh R, Weber MS, Bruck W, et al. B cells in multiple sclerosis therapy – a comprehensive review. Acta Neurol Scand. 2018;137(6):544–556.
   PubMed Web of Science ®Google Scholar
• Ellwardt E, Ellwardt L, Bittner S, et al. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e463.
   PubMed Web of Science ®Google Scholar
• Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342–1348.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• He D, Guo R, Zhang F, et al. Rituximab for relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev. 2013;12:Cd009130.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Harbour R, Lowe G, Twaddle S. Scottish Intercollegiate Guidelines Network: the first 15 years (1993–2008). J R Coll Physicians Edinb. 2011;41(2):163–168.
   PubMedGoogle Scholar
• NCCMT. Critical appraisal of non-randomized studies of interventions: ROBINS-I tool [Internet]. Hamilton (Canada): National Collaborating Centre for Methods and Tools; 2017 [cited 2020 Jan 15]. Available from: http://www.nccmt.ca/knowledge-repositories/search/281
   Google Scholar
• Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• NICE. The guidelines manual: process and methods [Internet]. London (UK): National Institute for Health and Care Excellence; 2012 [cited 2020 Jan 15]. Available from: https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-2007970804933
   Google Scholar
• Joseph JP, Cheong W, Thong J, et al. Mild infusion related adverse events of rituximab in multiple sclerosis: a case report. Mult Scler. 2012;18(4):543–544.
   Web of Science ®Google Scholar
• Holm F, Malmeström C, Novakova L, et al. Rituximab treatment of MS: a single centre retrospective observational study. Mult Scler. 2015;23(11):606.
   Google Scholar
• Malucchi S, Zecca C, Novi G, et al. Rituximab real life efficacy in MS: an observational multicentre study. Mult Scler J. 2017;23(3):320–321.
   Google Scholar
• Perez Miralles FC, Alcala Vicente C, Gascon Gimenez F, et al. Real-life experience with rituximab for the treatment of multiple sclerosis: report from two MS referral centres. Mult Scler J. 2017;23(3):343.
   Google Scholar
• Robers M, Tokhie H, Borazanci A. N-type calcium channel antibody encephalitis coexisting with multiple sclerosis. Neurology. 2018;90(15):5.
   Google Scholar
• Yamout BI, El-Ayoubi NK, Nicolas J, et al. Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. J Immunol Res. 2018;2018:1–9.
   Web of Science ®Google Scholar
• Spelman T, Frisell T, Piehl F, et al. Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing–remitting MS from the Swedish MS registry. Mult Scler. 2018;24(8):1087–1095.
   PubMed Web of Science ®Google Scholar
• Malucchi S, Capobianco M, Di Sapio A, et al. Rituximab as an effective treatment option after natalizumab withdrawal. Mult Scler. 2016;22:653–654.
   Web of Science ®Google Scholar
• Malucchi S, Capobianco M, Malentacchi M, et al. Rituximab treatment after natalizumab discontinuation in relapsing–remitting multiple sclerosis (RR-MS) patients with high risk of PML. Eur J Neurol. 2015;22:200.
   Web of Science ®Google Scholar
• Alldredge B, Jordan A, Imitola J, et al. Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clin Neuropharmacol. 2018;41(2):56–59.
   PubMed Web of Science ®Google Scholar
• Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320–327.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis. Neurology. 2016;87(20):2074–2081.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PAJ, Arnlod D, et al. Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400.
   PubMed Web of Science ®Google Scholar
• De Flon P, Gunnarsson M, Laurell K, et al. Reduced inflammation in relapsing–remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87(2):141–147.
   PubMed Web of Science ®Google Scholar
• Lo Re M, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther. 2015;4(2):147–157.
   PubMed Web of Science ®Google Scholar
• Barra ME, Soni D, Vo KH, et al. Experience with long-term rituximab use in a multiple sclerosis clinic. Mult Scler J Exp Translat Clin. 2016. doi:10.1177/2055217316672100
   PubMedGoogle Scholar
• Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–958.
   PubMed Web of Science ®Google Scholar
• Shahmohammadi S, Sahraian MA, Shahmohammadi A, et al. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Mult Scler Relat Disord. 2018;22:22–26.
   PubMed Web of Science ®Google Scholar
• Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler J. 2018;24(9):1224–1233.
   PubMed Web of Science ®Google Scholar
• Topping J, Dobson R, Lapin S, et al. The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult Scler Relat Disord. 2016;6:49–53.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghi A, Chisari CG, et al. Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord. 2019;27:324–326.
   PubMed Web of Science ®Google Scholar
• Ellrichmann G, Bolz J, Peschke M, et al. Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol. 2019;266(1):57–67.
   PubMed Web of Science ®Google Scholar
• Scotti B, Disanto G, Sacco R, et al. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLOS One. 2018;13(5):e0197415.
   PubMed Web of Science ®Google Scholar
• Boremalm M, Juto A, Axelsson M, et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. Eur J Neurol. 2019;26(8):1060–1067.
   PubMed Web of Science ®Google Scholar
• Salzer J, Boremalm M, Juto A, et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing–remitting multiple sclerosis. Mult Scler J. 2017;23(3):323.
   Google Scholar
• Durozard P, Maarouf A, Audrey R, et al. Efficacy of rituximab as a rescue therapy after the failure of second line treatment in relapsing remitting multiple sclerosis: a retrospective observational monocenter study. Mult Scler J. 2017;23(3):608.
   Google Scholar
• Stüve O, Leussink VI, Fröhlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing–remitting multiple sclerosis. Arch Neurol. 2009;66(2):259–261.
   PubMedGoogle Scholar
• Chaudhry B, Willis MA, Cohen JA. Acute tumefactive demyelination in a patient on rituximab; a case report. Mult Scler J. 2017;23(S3):680–975.
   PubMedGoogle Scholar
• Rodriguez EL, Vinagre A, Beatriz B, et al. Rituximab in high activity MS patients after natalizumab withdrawal. Mult Scler. 2014;20(1):449–450.
   Google Scholar
• Berenguer-Ruiz L, Sempere AP, Gimenez-Martinez J, et al. Rescue therapy using rituximab for multiple sclerosis. Clin Neuropharmacol. 2016;39(4):178–181.
   PubMed Web of Science ®Google Scholar
• Sempere AP, Berenguer-Ruiz L, Gabaldon-Torres L, et al. Rescue therapy with rituximab in multiple sclerosis. Mult Scler. 2013;19(11):509.
   PubMed Web of Science ®Google Scholar
• Cordioli C, De Rossi N, Rasia S, et al. Rituximab treatment of highly active multiple sclerosis (MS) after natalizumab-related progressive multifocal leukoencephalopathy (PML). Neurology. 2016;86(16):6.
   Google Scholar
• Hagens MH, Killestein J, Yaqub MM, et al. Cerebral rituximab uptake in multiple sclerosis: a 89Zr-immunoPET pilot study. Mult Scler. 2017;24(4):543–545.
   PubMed Web of Science ®Google Scholar
• Alcalá C, Gascon F, Perez-Miralles F, et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265(7):1690–1697.
   PubMed Web of Science ®Google Scholar
• Durozard P, Maarouf A, Boutiere C, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2018;25(6):828–836.
   PubMed Web of Science ®Google Scholar
• Berntsson SG, Kristoffersson A, Bostrom I, et al. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden – outlier or predecessor? Acta Neurol Scand. 2018;138(4):327–331.
   PubMed Web of Science ®Google Scholar
• Mancinelli CR, Scarpazza C, Santuccio G, et al. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help? Neurol Sci. 2018;39(5):965–966.
   PubMed Web of Science ®Google Scholar
• Perez Miralles FC, Alcala Vicente C, Gascon Gimenez F, et al. Real-life experience with rituximab for the treatment of multiple sclerosis: report from two MS referral centres. Multiple Sclerosis J. 2017;23(3):343.
   Google Scholar
• Larivee N, Suissa S, Khosrow-Khavar F, et al. Drospirenone-containing oral contraceptive pills and the risk of venous thromboembolism: a systematic review of observational studies. BJOG: Int J Obstet Gy. 2017;124(10):1490–1499.
   PubMed Web of Science ®Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–191.
   PubMed Web of Science ®Google Scholar
• Marcinno A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e498.
   PubMed Web of Science ®Google Scholar
• Hu Y, Nie H, Yu HH, et al. Efficacy and safety of rituximab for relapsing–remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(5):542–548.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, Version 5.1.0. Oxford, UK: The Cochrane Collaboration; 2011.
   Google Scholar
• Viswanathan M, Patnode CD, Berkman ND, et al. Assessing the risk of bias in systematic reviews of health care interventions. In: Methods guide for effectiveness and comparative effectiveness reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2008. p. 193–221.
   Google Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453.
   PubMed Web of Science ®Google Scholar